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Background & Aims: Azathioprine is effective for Crohn’s
disease but acts slowly. A loading dose may decrease
the time to response. Methods: A placebo-controlled
study was conducted in patients with active Crohn’s
disease despite prednisone treatment. Patients were
randomized to a 36-hour infusion of azathioprine, 40
mg/kg (51 patients), or placebo (45 patients) followed
by oral azathioprine, 2 mg/kg, for 16 weeks. Predni-
sone was tapered over 5 weeks. The primary outcome
measure was complete remission at week 8, defined
by discontinuation of prednisone and a Crohn’s Dis-
ease Activity Index ofI150 points. Erythrocyte concen-
trations of the azathioprine active metabolite, 6-thio-
guanine nucleotide, were measured. Results: At week
8, 13 patients (25%) were in complete remission in the
azathioprine-loaded group compared with 11 patients
(24%) in the placebo group. The frequency of complete
remission did not increase after 8 weeks in either
group. Both groups achieved steady state of 6-thiogua-
nine nucleotide by week 2, and no differences were
found in mean concentrations between the groups.
There were no significant differences in the frequency
of adverse events between the groups. Conclusions: A
loading dose does not decrease the time to response
in patients with steroid-treated Crohn’s disease begin-
ning azathioprine therapy. Steady state of erythrocyte
6-thioguanine nucleotide and complete response oc-
curred earlier than previously reported.
In the treatment of Crohn’s disease, 6-mercaptopurine(6MP) and its prodrug azathioprine (AZA) are effica-
cious.1–8 However, widespread use of these medications is
limited by the perception that they have a slow onset of
action. Present et al.4 reported that the mean time to
response in patients with Crohn’s disease treated with
6MP was 3.1 months and that 19% of responders
required 4 months or more of treatment before improve-
ment was observed. In a meta-analysis of all placebo-
controlled trials of AZA/6MP for Crohn’s disease, Pearson
et al.8 reported that a consistent clinical benefit for
AZA/6MP therapy was observed only after 17 weeks or
more of therapy. The reason that AZA/6MP may act
slowly is unclear. Some small pharmacokinetic studies
have reported that the active metabolites of AZA/6MP,
the 6-thioguanine nucleotides (6TGN), have a long
half-life resulting in slow accumulation in red blood cells
(RBCs) and other body tissues and the need for prolonged
treatment to reach steady state.9,10 Other studies have
reported that RBC 6TGN steady state is reached within
14–21 days in most patients.11,12 These pharmacological
observations raised the possibility that administration of
a loading dose of AZA or 6MP could accelerate their
onset of action. An open-label pilot study reported that
patients with refractory Crohn’s disease treated with an
intravenous (IV) loading dose of AZA (1800 mg [20–44
mg/kg] over 36 hours) achieved a steady state of RBC
6TGN within 3 days and experienced rapid clinical
Abbreviations used in this paper: AZA, azathioprine; IBDQ, Inflam-
matory Bowel Disease Questionnaire; 6MP, 6-mercaptopurine; 6TGN,
6-thioguanine nucleotides; TPMT, thiopurine methyltransferase; WBC,
white blood cell.
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benefit.13 Based on these preliminary results, we con-
ducted a 16-week placebo-controlled trial of an IV AZA
loading dose of 40 mg/kg in patients with active




The study was performed between September 1996 and
November 1997. Eligible patients were at least 18 years of age
and had active steroid-treated Crohn’s disease, as defined by a
score of 150–450 on the Crohn’s Disease Activity Index
(CDAI) and treatment with prednisone at a dose of $20
mg/day for $4 weeks. The CDAI assesses 8 variables: the
number of liquid stools, extent of abdominal pain, general
well-being, occurrence of extraintestinal symptoms, need for
antidiarrheal drugs, presence of abdominal masses, hematocrit,
and body weight.14 Scores can range from 0 (no active disease)
to approximately 600 (severe disease). Scores of 150–450 are
associated with disease that is mildly to moderately active.
Scores of ,150 indicate remission.
Eligible patients had disease that involved the ileum,
ileocolon, or the colon, verified previously by colonoscopy,
barium enema, or small bowel follow-through. Patients with
currently present fistulas involving adjacent loops of bowel
(enteroenteric fistulas) or the perianal region were eligible. In
addition, patients had to have normal metabolism of AZA as
defined by normal activity of the major catabolic enzyme for
AZA, thiopurine methyltransferase (TPMT).15 The following
patients were not eligible: those with active Crohn’s disease
isolated to the duodenum, jejunum, or perianal region; those
with currently present ileostomy or colostomy, septic complica-
tions, abscess, perforation with acute abdomen, or fistulas
involving the skin, bladder, or vagina; those who had a stricture
of the ileum or colon resulting in symptomatic obstruction
(confirmed by endoscopic or radiological studies) within 6
months; those who had undergone resection of more than 100
cm of the ileum; or those requiring immediate surgery. Before
the study, no patient received biotechnology therapies within 6
months, immune modifier drugs within 3 months, or antibiot-
ics or mesalamine within 2 weeks, similar to the criteria used in
other controlled trials of medical therapy for active Crohn’s
disease.16–18 Patients with a history of cancer of any type,
definite dysplasia of the colon within 5 years, or clinically
significant renal or hepatic disease were ineligible, as were
pregnant or breast-feeding women, patients who were allergic
to 6MP or AZA, and patients receiving allopurinol. The study
was approved by the institutional review board at each center,
and all participants gave written informed consent.
Study Medication
The IV AZA loading dose of 40 mg/kg over 36 hours
was chosen based on the preliminary data from a pilot study
showing that an IV AZA loading dose of 20–44 mg/kg was safe
and of apparent benefit13 and data from phase I studies of
continuous infusion 6MP for chemotherapy that showed
significant toxicity with 6MP doses of 50 mg · m2 · h21 for 48
and 60 hours, and minimal toxicity with doses of 50 mg · m2 ·
h21 for 12, 24, and 36 hours.19,20 Assuming a body surface of
1.73 m2 and a body weight of 70 kg for the average adult, and a
conversion factor of 2.07 for comparing 6MP with AZA (given
88% conversion of AZA to 6MP, and a molecular weight ratio
of 0.55), 6MP infusions at 50 mg · m2 · h21 for 12, 24, 36, 48,
and 60 hours would be comparable with 31, 61, 92, 123, and
153 mg/kg. Thus, the AZA loading dose of 40 mg/kg used in
the present study is comparable with the 6MP dose of 50 mg ·
m2 · h21 for 12–24 hours, at which only minimal toxicity
occurred.
Unblinded study pharmacists at each center prepared the IV
infusions (AZA or placebo). For patients treated with AZA, the
pharmacist determined the total amount of AZA to be
administered (based on a total AZA dose of 40 mg/kg), divided
the total amount by 3, reconstituted the appropriate number of
100-mg vials of AZA for injection (Imuran; Glaxo Wellcome,
Research Triangle Park, NC), added the appropriate amount of
reconstituted AZA into an empty 1000-mL Viaflex bag (Baxter
Medical, Round Lake, IL), and added normal saline to obtain a
total infusion volume of 600 mL. For patients treated with
placebo, the pharmacist added 3 mL of Multi-Vitamins for
Infusion (Schein Pharmaceuticals, Inc., Florham, NJ) and 597
mL of normal saline into an empty 1000-mL Viaflex bag
(Baxter Medical). Patients then received 3 consecutive 600-mL
infusions of study medication (AZA or placebo), each adminis-
tered continuously at a rate of 50 mL/h for 12 hours. Both
reconstituted AZA and multivitamins had a similar yellowish
appearance designed to blind patients, investigators, and
medical personnel caring for the patient to the treatment
allocation. To further maintain blinding, the study pharmacist
applied opaque sleeves to the infusion bags.
The oral AZA formulation used is a scored tablet containing
50 mg of AZA (Imuran, Glaxo Wellcome). The total daily dose
of oral AZA was based on body weight (2.0 mg/kg), rounded
upward to the nearest 25 mg. This dose of oral AZA, which was
at the lower end of the range of AZA doses previously reported
to be effective for Crohn’s disease,8 was chosen to give a margin
of safety in patients who had just completed an IV loading dose
of AZA of 40 mg/kg. The entire dose of AZA, 2.0 mg/kg, was
administered as a single daily dose beginning on day 3 of the
study. If patients developed laboratory abnormalities consistent
with hepatotoxicity (levels of aspartate aminotransferase . 53
normal or alkaline phosphatase . 33 normal), leukopenia
(total white blood cell count , 3.0 3 109/L), or thrombocyto-
penia (platelet count , 100 3 109/L), then AZA administra-
tion was discontinued until the abnormality resolved, and AZA
was restarted at 1.0 mg · kg21 · day21. Decisions regarding
AZA discontinuation or dose adjustments in patients who
experienced infection, fever, rash, arthralgias, malaise, and
nausea were handled on a case-by-case basis. If patients
developed pancreatitis or malignancy, AZA administration was
discontinued. Compliance with oral AZA therapy was deter-
mined by pill count.
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Prednisone Therapy
At the time of enrollment into the study (2 weeks
before randomization), all patients had their prednisone dose
adjusted to 20 mg/day, similar to the method reported
previously by Feagan.21 Thus, patients taking prednisone at a
dose . 20 mg/day had their dose immediately reduced to 20
mg/day (regardless of the duration of steroid therapy or the
duration of time at the current steroid dose); and patients
taking 20 mg prednisone daily continued at that dose. For 2
weeks after randomization, no attempt was made to decrease
the prednisone dose. After the first follow-up visit (at week 2),
the daily prednisone dose was decreased by 5 mg each week.
Prednisone was discontinued at the beginning of week 6. In
subjects whose condition worsened (increase in the CDAI .
100 points above baseline or CDAI . 450), the prednisone
dose was increased to 40 mg/day for 1 week and decreased by 5
mg each week until prednisone was discontinued.
Design of the Study
The study was a randomized, double-blind, placebo-
controlled trial performed at 16 centers in the United States
and Canada. Patients were stratified according to treatment
center and randomized separately in permuted blocks of 2 by
the unblinded study pharmacist at each center using a
computer-generated randomization scheme. The blinded 36-
hour infusion of 40 mg/kg AZA or placebo was followed by 16
weeks of open therapy with oral AZA, 2.0 mg · kg21 · day21.
The study duration of 18 weeks (2-week period of equilibration
after standardization of prednisone and withdrawal of mesala-
mine and antibiotics, and then 16 weeks of AZA therapy) was
based on the hypothesis that an IV AZA loading dose would
accelerate the onset of action of AZA (making a long-term trial
unnecessary) and on a meta-analysis of previous studies of oral
AZA for active Crohn’s disease, which showed that the odds
ratio for response became significant with a study duration of
17 weeks.8
At entry, each patient’s demographic characteristics, medical
history, and current medications were recorded. Disease activ-
ity was assessed before treatment (after 2 weeks of screening
observation); after 2, 4, 8, 12, and 16 weeks of treatment; and
in the event that treatment was discontinued. Efficacy was not
evaluated after the discontinuation of treatment in patients
who withdrew from the study before week 16. At each visit, a
physical examination, quality-of-life assessment, laboratory
tests, and a global evaluation were conducted, and patients
were asked whether any adverse events had occurred. No
medications for Crohn’s disease other than prednisone, the
study drug, and antidiarrheals (loperamide, diphenoxylate, or
opiates) were allowed.
Quality of life was assessed with the self-administered
Inflammatory Bowel Disease Questionnaire (IBDQ), a previ-
ously validated instrument with 4 parts (bowel function,
emotional status, systemic symptoms, and social function); the
total score on this index ranges from 32 to 224, with higher
scores indicating better quality of life. The scores of patients in
remission usually range from 170 to 190.22
Patients recorded on diary cards their intake of study
medication and prednisone, the frequency of loose stools, the
extent of their abdominal pain, and general well-being during
the 7 days before each visit. Blood samples were taken for
hematologic and biochemical assessments and liver function
tests. Blood was drawn for measurement of RBC TPMT
enzyme activity at the screening visit (Mayo Medical Laborato-
ries, Rochester, MN). The activity of the TPMT enzyme is
subject to significant genetic variation.15 There is a trimodal
distribution of TPMT activity in the general population: low
TPMT activity (,5.0 U/mL RBC) occurs at a frequency of
0.3%; intermediate TPMT activity (5.0–13.7 U/mL RBC)
occurs at a frequency of 11.1%; and high or normal TPMT
activity (13.8–25.1 U/mL RBC) occurs at a frequency of
88.6%.15 Blood was also drawn for measurement of the active
metabolite of AZA, 6TGN, in RBCs. The total RBC 6TGN
concentration is based on the conversion of 6TGN to the free
6TGN base, which is then oxidized to a fluorescent sulfonate
and assayed by high-performance liquid chromatography.13,23
The intracellular 6TGN concentration thus represents the total
RBC 6TGN contents consisting of a composite of the mono-,
di-, and triphosphate nucleotides. The RBC 6TGN concentra-
tion is normalized to 8 3 108 RBCs. The assay is sensitive to 30
pmol with an overall interday coefficient of variance of 5%, as
described previously.13 The therapeutic range for RBC 6TGN
in patients treated with AZA is unknown.
All adverse events were recorded, whether or not they were
related to the study medication. A serious adverse event was
defined as one that was life threatening or led to permanent
disability, hospitalization, or death. The intensity of adverse
events was graded as mild, moderate, or severe, with a severe
event considered to be one that was incapacitating, leading to
an inability to work or take part in normal activities.
Statistical Analysis
We estimated that 36 patients were needed in each
group to detect an absolute difference of 35% between groups
in the proportion of patients in complete remission, assuming
complete remission rates of 60% with IV AZA treatment
compared with 25% with standard oral AZA, and 80% power.
We planned to recruit a total of 90 patients to allow for a
dropout rate of up to 20%.
The primary outcome was the rate of complete remission,
defined as a CDAI score , 150 points and total steroid
withdrawal at week 8. The primary intention-to-treat popula-
tion (as stated in the study protocol) included all patients who
received at least one dose of study medication. Secondary end
points were clinical remission (defined as a CDAI score , 150
points), clinical improvement (defined as a CDAI score , 150
points or total steroid withdrawal), clinical improvement
(defined as a decrease in baseline CDAI $ 70 points), mean
daily prednisone dose, mean CDAI scores, mean IBDQ scores,
mean RBC 6TGN concentrations, mean white blood cell
(WBC) concentrations, and adverse events.
The rates of complete remission were compared using a
Mantel–Haenszel x2 test controlling for geographic cluster.
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Clusters were used to ensure adequate representation across
treatment groups and to minimize disproportionate influence
by any given center. Comparisons of more than 2 rates were
made using an extended Mantel–Haenszel test. Clinical remis-
sion and adverse event rates were compared using the Fisher
exact test. A van Elteren test was use to compare the medians
for CDAI scores, IBDQ scores, daily prednisone use, RBC
6TGN concentrations, and WBC concentrations. All tests were
two-sided. P values , 0.05 were considered to indicate
statistical significance.
For analysis of remission rates at 8, 12, and 16 weeks, we
divided the number of patients in the group who were
evaluated and in remission at that time, or who had already
been withdrawn from the study while in remission, by the
number of patients who were evaluated at that time or who had
withdrawn before that time (last observation carried forward
principle). The secondary end points of clinical remission and
the 2 definitions of clinical improvement at 2, 4, 8, 12, and 16
weeks were analyzed similarly. In the analysis of RBC 6TGN
and WBC concentrations, data on patients who were lost to
follow-up or withdrawn from the study because of deterioration
in their condition or adverse events were censored at the time of
the last study visit.
Results
A total of 96 patients were enrolled; 51 were
randomly assigned to receive IV AZA and 45 were
assigned to receive placebo. All patients received the IV
study medication and were included in the intention-to-
treat analysis. The baseline characteristics of the 2 groups
of patients were similar (Table 1). Thirty-two patients
(63%) in the IV AZA group and 26 patients (58%) in the
placebo group (P 5 0.679) completed the scheduled 16
weeks of treatment and follow-up. Worsening Crohn’s
disease led to withdrawal of 5 patients in the IV AZA
group and 4 patients in the placebo group. Adverse
events led to the withdrawal of 8 patients in the IV AZA
group and 12 patients in the placebo group. One patient
in the IV AZA group declined to continue. Protocol
violations led to withdrawal of 3 patients in the IV AZA
group and 1 patient in the placebo group. In both groups,
2 patients were withdrawn for other reasons. The median
compliance for oral AZA therapy was 96% in the IV
AZA group and 91% in the placebo group.
Clinical Efficacy
The rates of complete remission were similar in
the IV AZA and placebo groups throughout the study.
The respective rates were 25% and 24% (P 5 0.906) after
8 weeks, 22% and 22% (P 5 0.939) after 12 weeks, and
31% and 27% (P 5 0.615) after 16 weeks (Figure 1).
Other measures of response including clinical remission
and the 2 types of clinical improvement were also similar
in the IV AZA and placebo groups throughout the study.
The respective rates of clinical remission (CDAI , 150),
clinical improvement (CDAI , 150 or total steroid
withdrawal), and clinical improvement (decrease in base-
line CDAI $ 70 points) after 2, 4, 8, 12, and 16 weeks
are shown in Figure 1. The median time to first clinical
remission (CDAI , 150) was identical in the IV AZA
and placebo groups (28 vs. 28 days; P 5 0.984).
The median scores on the CDAI, the IBDQ quality of
life index, and the median daily prednisone doses were
similar in the IV AZA and placebo groups throughout
the 16-week study (Figure 2). The rate of complete
remission (CDAI , 150 and total steroid withdrawal)
was not significantly greater in patients in either treat-
ment group who had a shorter duration of steroid therapy
(#90 days) than in patients who had a longer duration of
steroid therapy ($91 days). The IV AZA and placebo
groups were similar with respect to the percentage of
patients who had previously been treated with AZA/6MP
(27% vs. 16%; P 5 0.179), cyclosporine (8% vs. 7%;
P 5 0.813), and methotrexate (21% vs. 13%; P 5
0.410). There were no significant differences in the rates






Sex (M/F) 25/20 24/27






Duration of disease ( yr )
Median 6.6 7.1
Range 0–35 0–28





Median score 245 244
Range 142–476 89–424
IBDQ









Previous intestinal resection (no.
of patients) 26 16
Cigarette smoker (no. of patients) 16 22
Duration of steroid use (days)
Median 70 70
Range 29–7300 3–330
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of complete remission in the IV AZA and placebo groups
when stratified according to previous therapy with
AZA/6MP, cyclosporine, or methotrexate.
Azathioprine Dose, 6TGN Concentrations,
TPMT Activity, and WBC Concentrations
The median baseline RBC TPMT activities were
similar in the IV AZA and placebo groups (Table 1). The
median RBC 6TGN concentrations were significantly
greater at the end of the 36-hour infusion (week 0.2) and
at week 1 in the IV AZA group but were similar at all
other time points throughout the 16-week study (Figure
2). The overall mean daily doses of oral AZA in the IV
AZA and placebo groups (2.00 6 0.31 and 2.15 6 0.24
mg/kg, respectively) were associated with overall mean
RBC 6TGN concentrations using within subject means
of 164 6 61 and 124 6 67 pmol/8 3 108 RBCs. The
correlation between the baseline TPMT activities and the
mean within subject RBC 6TGN concentrations over 16
weeks in the combined patient groups was r 5 20.0137,
P 5 0.8975. The rate of complete remission (CDAI ,
150 and total steroid withdrawal) was not significantly
greater in patients with 6TGN concentrations of $200
pmol/8 3 108 RBCs.
The mean total WBC concentrations were signifi-
cantly lower at weeks 1 and 2 in the IV AZA group than
in the placebo group but were otherwise similar through-
out the 16-week study (Figure 2). The correlation
between the total WBC concentrations and the corre-
sponding RBC 6TGN concentrations in each patient in
the combined patient groups over weeks 1–16 was r 5
20.11, P 5 0.30. The rate of complete remission
(CDAI , 150 and total steroid withdrawal) was not
significantly greater in patients with mild leukopenia
(defined as a total WBC concentration # 5.0 3 108/L).
Adverse Events
The numbers of patients with adverse events were
similar in the 2 groups, with the exception of nausea and
infusion site reactions, which were more common in the
IV AZA group; the most frequent adverse events and
adverse events known to be associated with AZA are
shown in Table 2. Serious adverse events and severe
adverse events were also similar in both groups. Aside
from the decrease in the mean total WBC concentrations
in the IV AZA group at weeks 1 and 2 (discussed above),
there were no clinically significant changes in any other
hematologic or biochemical variables in either group.
Figure 1. Percentages of patients with Crohn’s disease with improvement or remission at each study visit, according to treatment group. 5,
Placebo; L, IV AZA. There were no significant differences between the 2 groups at any time point. (A) Complete remission (CDAI score , 150
points and total steroid withdrawal). (B) Clinical remission (CDAI score , 150 points). (C) Improvement (CDAI score , 150 points or total steroid
withdrawal). (D) Improvement (decrease in CDAI score from baseline $ 70 points).
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Discussion
We found that administration of a loading dose of
IV AZA does not decrease the time to response or increase
the response rate in patients with active steroid-treated
Crohn’s disease beginning oral AZA treatment. The
condition of patients in both groups improved after 2
weeks and reached a plateau after 4 weeks. The degree of
response was similar in the 2 groups throughout the
study, as measured by complete remission, clinical remis-
sion, and the 2 types of clinical improvement. Other
measures of response, such as a decrease in mean daily
prednisone dose and an increased quality of life, also
showed a similar degree of improvement in the 2 groups
throughout the study. The duration of prestudy steroid
therapy had no effect on response. The relatively high
rates of early withdrawal (37% for the IV AZA group and
42% for the placebo group) are similar to those in other
studies of medical therapy for active Crohn’s disease.16–18,21
Given the size of this study and the comprehensive nature
of the outcome measures, it is unlikely that a clinically
important benefit went undetected. Based on these
findings, we do not recommend the use of an IV loading
dose of AZA in patients with Crohn’s disease who are
beginning oral AZA treatment.
One assumption that our study was based on is that
AZA and 6MP have a slow onset of action. The results of










No. of adverse events 185 258 0.730
No. of patients with adverse events 40 (89%) 47 (92%) 0.730
No. of patients with serious adverse
events 11 (24%) 13 (25%) 1.000
No. of patients with severe adverse
events 14 (31%) 19 (37%) 0.667
Most frequent adverse events (no. of
events)
Nausea 15 (33%) 28 (55%) 0.041
Injection site reaction 1 (2%) 11 (22%) 0.005
Headaches 10 (22%) 7 (14%) 0.298
Malaise and fatigue 9 (20%) 8 (16%) 0.604
Vomiting 8 (18%) 9 (18%) 1.000
Viral lower respiratory infection 6 (13%) 6 (12%) 1.000
Abdominal pain 5 (11%) 5 (10%) 1.000
Arthralgias 3 (7%) 5 (10%) 0.719
Adverse events commonly associated
with AZA (no. of events)
Leukopeniaa 5 (11%) 5 (10%) 1.000
Pneumonia 2 (4%) 0 (0%) 0.217
Thrombocytopenia 0 (0%) 2 (4%) 0.497
Pancreatitis 2 (4%) 0 (0%) 0.497
Abnormal liver function tests 1 (2%) 0 (0%) 0.469
Fever 4 (9%) 4 (8%) 1.000
Rash 2 (4%) 3 (6%) 1.000
aClinically significant leukopenia defined as a total WBC ,3.0 3
108/L.
Figure 2. Median scores or values at each study visit according to treatment group. d, Placebo; m, IV AZA. The only significant differences
between the 2 groups at any of the time points are those indicated in the figure. (A) CDAI and IBDQ quality of life index. (B) Prednisone dose. (C)
RBC 6TGN nucleotide concentrations. (D) Total WBC concentrations.
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the study suggest that this assumption may be incorrect
and that the evidence underlying this belief should be
reexamined. The results from 3 placebo-controlled trials
of oral AZA for active Crohn’s disease published in the
early 1970s can probably be dismissed as invalid because
of methodological problems including small sample size,
crossover design, and use of unvalidated end points.1,24,25
In 1980, Present et al.4 reported a placebo-controlled trial
showing that oral 6MP was effective for active Crohn’s
disease. Although this important study established a role
for 6MP/AZA in the treatment of Crohn’s disease,
methodological problems including a heterogenous pa-
tient population, crossover design, use of unvalidated end
points, and infrequent assessments of clinical response
make poststudy subgroup analyses and observations
suspect. In particular, the authors’ assertion that the mean
time to response was 3.1 months may represent an
overestimate because patients were only clinically as-
sessed every 3 months. Two other placebo-controlled
studies of oral AZA or 6MP failed to show efficacy at
week 12 but did show efficacy at 12–15 months.6,7 In
these studies, initial combination therapy with high-dose
corticosteroids, which was tapered slowly over 12 weeks
or more, makes it difficult to determine the time to
response for AZA/6MP. In the National Cooperative
Crohn’s Disease Study, monotherapy with oral AZA was
compared with placebo.26 There was a trend toward a
benefit for AZA-treated patients that did not reach
statistical significance. The maximum decrease in the
mean CDAI score for the AZA-treated patients occurred
at 9 weeks. In another study, oral AZA administered in
combination with high-dose corticosteroids (which were
rapidly tapered to 10 mg/day over 6 weeks) showed a
significant benefit for AZA by week 8.5 Finally, our study
showed that patients in the placebo group (who were
beginning standard oral AZA therapy) reached a plateau
of the proportion of patients who experienced a clinical
response after 4 weeks. These findings suggest that oral
AZA or 6MP may act more rapidly than previously
believed, perhaps over 4–8 weeks.
Without a placebo control group, it is difficult to
directly compare the complete remission rates in our
study (31% for the IV AZA group and 27% for the
standard oral AZA group at 16 weeks) with those of other
controlled trials of oral AZA for active Crohn’s disease.
Nevertheless, the remission rates in our study seem to be
generally lower than those previously reported.8 The
likely explanation is that the patients entering our trial
were steroid refractory and that we required complete
steroid withdrawal as part of the definition of remission.
The remission rates in our study seem similar to 2 other
recent trials of methotrexate and infliximab for active
Crohn’s disease refractory to steroids and other medical
therapies.21,27
Another assumption that our study was based on is
that 6TGN accumulates slowly in RBCs and other body
tissues, and prolonged treatment with oral AZA/6MP is
required to reach steady state. The results of our study
indicate that this assumption is incorrect. We showed
that steady-state concentrations of RBC 6TGN were
achieved by 2 weeks in patients in the placebo group who
were beginning standard oral AZA treatment. Although
the mean RBC 6TGN concentrations were significantly
higher in the IV AZA group at weeks 0.2 and 1, they
were similar beginning at week 2 for the remainder of the
16-week study. Our results corroborate the findings of 2
other pharmacokinetic studies in patients with acute
lymphoblastic leukemia or renal allografts treated with
6MP or AZA in which RBC 6TGN concentrations were
reported to reach steady state in 14–21 days.11,12 These
findings show that patients with active Crohn’s disease
treated with oral AZA reach steady-state concentrations
of RBC TGN over 2–3 weeks.
Our study does not clarify the clinical use of measuring
the activity of the major catabolic enzyme of AZA (RBC
TPMT) before starting oral AZA therapy and of doing
therapeutic drug monitoring with RBC 6TGN concentra-
tions during oral AZA therapy. Patients were eligible for
our study only if they had normal RBC TPMT activity,
leading to a relatively homogenous and low-risk patient
population. There was not a statistically significant
inverse correlation between baseline RBC TPMT activity
and mean within subject RBC 6TGN concentrations over
16 weeks. An inverse relationship would likely have been
shown if patients with intermediate and homozygous low
TPMT activity had been included, similar to previous
reports in children with acute lymphoblastic leukemia28
and adults with rheumatoid arthritis.29 We did not find
that RBC 6TGN concentrations of $200 pmol/8 3 108
RBCs were associated with a greater likelihood of
response. These findings are in contrast to a prior report
suggesting a correlation between clinical response and
RBC 6TGN in patients with Crohn’s disease treated with
a range of 6MP doses.30 The average RBC 6TGN
concentrations over 16 weeks in our patients treated with
IV placebo followed by 2 mg/kg oral AZA were relatively
low (mean, 124 pmol/8 3 108 RBCs) compared with
concentrations reported in patients with acute lymphoblas-
tic leukemia treated with 75 mg/m2 oral 6MP (median,
284 pmol/8 3 108 RBCs).31 To further explore the
potential use of RBC 6TGN therapeutic drug monitor-
ing in patients treated with oral AZA, additional studies
including patients with intermediate or homozygous low
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TPMT activity and exploring a range of oral AZA doses
(perhaps 0.5–4.0 mg/kg) should be undertaken.
There was a significant but transient decrease in the
mean total WBC concentration in the IV AZA group at
weeks 1 and 2; otherwise both study groups had a parallel
decrease in the mean total WBC concentration that
plateaued at week 8. Ten percent of patients in the IV
AZA group developed clinically significant leukopenia
(total WBC , 3.0 3 108/L) during the study compared
with 11% in the placebo group. The rate of leukopenia in
the placebo group (standard oral AZA) is similar to the
leukopenia rates of 2%–11% reported in other safety
studies of AZA and 6MP in patients with IBD.32–34
There was not a statistically significant inverse correla-
tion between the total WBC concentrations and the
corresponding RBC 6TGN concentrations over weeks
1–16. An inverse relationship would likely have been
shown if patients with intermediate or homozygous low
TPMT activity and a wider range of AZA doses had been
included, similar to a previous report in children with
acute lymphoblastic leukemia.35 We were not able to
identify a cutoff value for the RBC 6TGN concentration
that accurately predicted leukopenia. A retrospective
study suggested an association between mild leukopenia
(defined as a total WBC concentration # 5.0 3 108/L)
and remission in patients with Crohn’s disease treated
with 6MP.36 In our study, the rate of complete remission
(CDAI , 150 and total steroid withdrawal) was not
significantly greater in patients with mild leukopenia; we
are therefore unable to confirm to the previous associa-
tion.
AZA therapy was generally well tolerated in both
patient groups, and the frequency and type of AZA-
associated adverse events observed were similar to those
reported in other studies.32–34 The frequency of severe
and serious adverse events (according to World Health
Organization definitions) was relatively high, but gener-
ally comparable with other studies of medical therapy for
active Crohn’s disease.17,18,21,27 The serious adverse events
were all related to need for hospitalization, in most cases
because of worsening of Crohn’s disease. Our results show
that pretreatment with an IV AZA loading dose before
beginning oral AZA treatment, although not of clinical
benefit, is as safe as standard treatment with oral AZA in
patients with normal RBC TPMT activity.
In conclusion, a loading dose is safe but not effective in
decreasing the time to response in patients with steroid-
treated Crohn’s disease beginning AZA treatment. Steady-
state concentrations of RBC 6TGN and clinical improve-
ment/remission in patients receiving standard oral AZA
occurred earlier than previously reported. Additional
studies to explore the time to response, the dose response,
and the clinical use of therapeutic drug monitoring in
patients with Crohn’s disease treated with oral AZA are
warranted.
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